Report overview
Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
This report aims to provide a comprehensive presentation of the global market for Anti-Obesity Prescription Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Obesity Prescription Drugs. This report contains market size and forecasts of Anti-Obesity Prescription Drugs in global, including the following market information:
Global Anti-Obesity Prescription Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Anti-Obesity Prescription Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Anti-Obesity Prescription Drugs companies in 2022 (%)
The global Anti-Obesity Prescription Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Pediatric Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Anti-Obesity Prescription Drugs include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim and Alizyme, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Anti-Obesity Prescription Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-Obesity Prescription Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Anti-Obesity Prescription Drugs Market Segment Percentages, by Type, 2022 (%)
Pediatric
Adult
Global Anti-Obesity Prescription Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Anti-Obesity Prescription Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Global Anti-Obesity Prescription Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Anti-Obesity Prescription Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-Obesity Prescription Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Anti-Obesity Prescription Drugs revenues share in global market, 2022 (%)
Key companies Anti-Obesity Prescription Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Anti-Obesity Prescription Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-Obesity Prescription Drugs, market overview.
Chapter 2: Global Anti-Obesity Prescription Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-Obesity Prescription Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Anti-Obesity Prescription Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
